Perioperative anticoagulant management in patients with atrial fibrillation: Practical implications of recent clinical trials

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 9, 2015, Pages 666-671

  Tafur, Alfonso ^a,b   Douketis, James D ^c  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Atrial fibrillation; Perioperative; Procedure; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; HEPARIN; RIVAROXABAN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; CARDIOEMBOLIC STROKE; CARDIOVASCULAR RISK; CASE REPORT; CEREBROVASCULAR ACCIDENT; ELECTIVE SURGERY; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; KNEE ARTHROSCOPY; LONG TERM CARE; MALE; META ANALYSIS (TOPIC); OPERATIVE BLOOD LOSS; PACEMAKER IMPLANTATION; PERIOPERATIVE PERIOD; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SICK SINUS SYNDROME; SURGICAL RISK; THROMBOEMBOLISM; CLINICAL TRIAL (TOPIC); COMPLICATION; PRACTICE GUIDELINE; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; PERIOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; STROKE;

EID: 84943627620     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3049     Document Type: Review

References (29)

1. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013; 112: 1142-1147.
2. Kaatz S, Douketis JD, Zhou H, et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost. 2010; 8: 884-890.
3. Wysokinski WE, McBane RD 2nd. Periprocedural bridging management of anticoagulation. Circulation. 2012; 126: 486-490.
4. Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med. 2013; 368: 2113-2124.
5. Tafur A, Wysokinski WE, McBane RD 2nd. Periprocedural anticoagulant management. Hosp Pract (1995). 2012; 40: 40-49.
6. Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation. 2012; 126: 1573-1576.
7. Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012; 126: 1630-1639.
8. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging an-ticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015; 113: 625-632.
9. Birnie DH, Healey JS, Essebag V. Management of anticoagulation around pacemaker and defibrillator surgery. Circulation. 2014; 129: 2062-2065.
10. Robinson M, Healey JS, Eikelboom J, et al. Postoperative low-molecular-weight heparin bridging is associated with an increase in wound hema-toma following surgery for pacemakers and implantable defibrillators. Pacing Clin Electrophysiol. 2009; 32: 378-382.
11. Jamula E, Douketis JD, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. J Thromb Haemost. 2008; 6: 1615-1621.
12. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013; 368: 2084-2093.
13. Bajkin B V, Popovic SL, Selakovic SD. Randomized, prospective trial comparing bridging therapy using low-molecular-weight heparin with maintenance of oral anticoagulation during extraction of teeth. J Oral Maxillofac Surg. 2009; 67: 990-995.
14. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008; 51: 810-815.
15. Chen J Y, Zhang AD, Lu H Y, et al. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. J Geriatr Cardiol. 2013; 10: 258-266.
16. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging An-ticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015; 373: 823-833.
17. Arboix A, Alio J. Cardioembolic stroke: clinical features, specific cardiac disorders and prognosis. Current cardiology reviews. 2010; 6: 150-161.
18. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagula-tion with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005; 94: 528-531.
19. Tafur AJ, McBane R, 2nd, Wysokinski WE, et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost. 2012; 10: 261-267.
20. Omran H, Bauersachs R, Rubenacker S, et al. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012; 108: 65-73.
21. Tafur AJ, Wysokinski WE, McBane RD, et al. Cancer effect on peripro-cedural thromboembolism and bleeding in anticoagulated patients. Ann Oncol. 2012; 23: 1998-2005.
22. McBane RD, Wysokinski WE, Daniels PR, et al. Periprocedural antico-agulation management of patients with venous thromboembolism. Arterio-scler Thromb Vasc Biol. 2010; 30: 442-448.
23. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost. 2010; 8: 107-113.
24. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation. 2004; 110: 1658-1663.
25. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012; 120: 2954-2962.
26. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014; 35: 1888-1896.
27. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2014; 63: 982-988.
28. Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multi-center study. Heart rhythm. 2015; 12: 1162-1168.
29. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dab-igatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012; 59: 1168-1174.